Trials / Recruiting
RecruitingNCT06954740
Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This trial is to evaluate the efficacy and safety of Amimestrocel (human umbilical cord mesenchymal stromal cells) in the treatment of AKI patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amimestrocel | Amimestrocel will be administered at a target dose of 1×10E6 MSCs/kg body weight on day 1, 4, 8, 15. |
Timeline
- Start date
- 2025-06-10
- Primary completion
- 2026-05-15
- Completion
- 2028-05-15
- First posted
- 2025-05-02
- Last updated
- 2025-09-08
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06954740. Inclusion in this directory is not an endorsement.